Pacl*taxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial | Semantic Scholar (2024)

In this individual patient data (IPD) meta-analysis, it is demonstrated that combination-platinum chemotherapy improves OS and PFS across all subgroups, providing the strongest evidence to date of the benefit of combination-Platinum over single-agent platinum.

When the treatment-free interval was between 6 and 12 months, the extent of the benefit was less clear and further trials are certainly warranted, but evidence to support this comes from the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.

When the treatment-free interval was between 6 and 12 months, the extent of the benefit was less clear and further trials are certainly warranted, but evidence to support this comes from the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.

Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.

The introduction of novel agents without cross-resistance to platinum or taxanes has improved the prognosis of platinum-resistant patients, and this has not been clarified during the last decade.

Combination chemotherapy should be considered the standard treatment of recurrent platinum-sensitive ovarian cancer, but the choice of treatment needs to take into account the increase in side effects when using combination chemotherapy compared with carboplatin monotherapy, and the different toxicities of the two combination regimens.

In comparison with current standard protocols, a combination of docetaxel, gemcitabine, and oxaliplatin showed considerably higher efficacy without remarkable increased toxicity; particularly for patients with early relapse after a platinum-containing therapy.

The high level of activity and its duration observed warrants further evaluation of this combination in pretreated platinum-sensitive advanced ovarian cancer patients.

PLD plus carboplatin is highly effective, prolongs OS, and is well tolerated in women with AOC in late relapse previously treated with both platinum and taxanes.

...

...

Rechallenge with either single-agent pacl*taxel or platinum-based chemotherapy is effective in this patient population of previously treated patients with recurrent ovarian cancer.

There is strong and confirmatory evidence from two large randomized phase III trials to support pacl*taxel-cisplatin as the new standard regimen for treatment of patients with advanced ovarian cancer.

Re-treatment with carboplatin and pacl*taxel is effective as initial therapy in recurrent EOC and should form the basis of a randomized trial to determine the best agents for initial treatment of relapse from EOC in potentially platinum-sensitive patients.

The use of this combination of pacl*taxel and a platinum compound, in this sensitive population, has a high response rate and long progression-free interval and in a chemotherapy-sensitive population, the activity of alternative second-line agents must be interpreted with this perspective.

Primary responses to cisplatin/carboplatin-based treatment are common in patients with ovarian cancer who have previously responded to the agents and increase in frequency with greater distance from the initial therapy.

Cisplatin alone or in combination yielded superior response rates and PFS relative to pacl*taxel; however, OS was similar in all three arms, and the combination therapy had a better toxicity profile; therefore, the combination of cisplatin and pac litaxel remains the preferred initial treatment option.

Pacl*taxel has shown activity in women with platinum-refractory ovarian cancer, and it can be administered with an acceptable safety profile, and further research is needed to determine the optimal role of pacl*taxe in the primary and salvage treatment of ovarian cancer.

...

...